Name: mucopolysaccharidosis type II: a plain-language guide
Published: 2026-06-14

Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. mucopolysaccharidosis type II is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's mucopolysaccharidosis type II?

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive lysosomal storage disorder. A faulty IDS gene leaves the enzyme iduronate-2-sulfatase deficient, so the body cannot break down the glycosaminoglycans dermatan and heparan sulfate; these accumulate and damage many systems over time. It runs along a severity spectrum graded on one enzyme deficiency rather than separate diseases: a severe (neuronopathic) form with progressive cognitive decline, and an attenuated form without major central-nervous-system involvement. Because it is X-linked, it mainly affects males. It is distinct from MPS I (Hurler/Scheie, autosomal recessive, alpha-L-iduronidase) and the other MPS subtypes, which involve different enzymes.

Also indexed as	OMIM:309900, MONDO:0010674
Features mapped	14
Treatments mapped	2
Published sources	12
Last reviewed	2026-08-04

Signs and symptoms

Hepatosplenomegaly

An enlarged liver and spleen (hepatosplenomegaly) is a common finding, reflecting storage of glycosaminoglycans in those organs.

Limited evidenceSource: PMID:40102994

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, OMIM:309900

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary OMIM:309900 -> PMID:40102994 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Abnormal heart valve morphology

Heart valve disease is part of the cardiac involvement in MPS II; glycosaminoglycan storage thickens the valves and can affect how well they work.

Limited evidenceSource: PMID:41017152

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, ORPHA:580

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary ORPHA:580 -> PMID:41017152 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Splenomegaly

The spleen also enlarges as storage material accumulates, often together with an enlarged liver.

Limited evidenceSource: PMID:40102994

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesORPHA:580

Notesplain_language confirmed from PMID:40102994 via curation 2026-06-18 [claude (tier3 curation)]. | regrounded primary ORPHA:580 -> PMID:40102994 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Short stature

Short stature is frequently seen, part of the skeletal and growth effects of the condition.

Limited evidenceSource: PMID:41858182

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, ORPHA:580

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary ORPHA:580 -> PMID:41858182 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Inguinal hernia

Hernias, including in the groin, are common and often appear early, sometimes before the diagnosis is made.

Limited evidenceCurated reference: ORPHA:580

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:42148612

Notesplain_language confirmed from PMID:42148612 via curation 2026-06-18 [claude (tier3 curation)].

Last reviewed2026-06-18

Umbilical hernia

Hernias at the navel (umbilical) are also common early in Hunter syndrome and may need surgical repair.

Limited evidenceCurated reference: ORPHA:580

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:42148612

Notesplain_language confirmed from PMID:42148612 via curation 2026-06-18 [claude (tier3 curation)].

Last reviewed2026-06-18

Urinary glycosaminoglycan excretion

People with MPS II excrete excess glycosaminoglycans in the urine. Measuring urinary glycosaminoglycan levels supports diagnosis and is used to track response to treatment.

Limited evidenceSource: PMID:18245410

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:41232197, OMIM:309900

Notesplain_language confirmed from PMID:41232197 via curation 2026-06-14. | regrounded primary OMIM:309900 -> PMID:18245410 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Hearing impairment

Hearing loss is common in MPS II and may be conductive, sensorineural, or mixed; regular hearing assessment is part of routine care.

Limited evidenceSource: PMID:42107344

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, OMIM:309900

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary OMIM:309900 -> PMID:42107344 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Coarse facial features

Many people with MPS II develop coarse facial features over time, a recognized part of the storage process as glycosaminoglycans accumulate in tissues of the face.

Limited evidenceSource: PMID:41858182

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, ORPHA:580

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary ORPHA:580 -> PMID:41858182 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Hepatomegaly

Storage material builds up in the liver, so an enlarged liver (often with an enlarged spleen) is a common finding.

Limited evidenceSource: PMID:38053935

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40102994, ORPHA:580

Notesplain_language confirmed from PMID:40102994 via curation 2026-06-18 [claude (tier3 curation)]. | regrounded primary ORPHA:580 -> PMID:38053935 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Dysostosis multiplex

Dysostosis multiplex is the characteristic pattern of bone changes seen on X-rays in MPS II, affecting the skull, spine, ribs, and limbs.

Limited evidenceCurated reference: ORPHA:580

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14.

Last reviewed2026-06-14

Communicating hydrocephalus

Fluid can build up around the brain (hydrocephalus) in Hunter syndrome, which may raise pressure inside the head and sometimes needs a shunt.

Limited evidenceSource: PMID:40102994

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesORPHA:580

Notesplain_language confirmed from PMID:40102994 via curation 2026-06-18 [claude (tier3 curation)]. | regrounded primary ORPHA:580 -> PMID:40102994 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Global developmental delay

In the severe (neuronopathic) form, the brain is affected and children show developmental delay; the attenuated form typically spares cognition.

Limited evidenceSource: PMID:41964217

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40981299, ORPHA:580

Notesplain_language confirmed from PMID:40981299 via curation 2026-06-14. | regrounded primary ORPHA:580 -> PMID:41964217 on 2026-06-26 [Carrie Schluter, BCPA]

Last reviewed2026-06-26

Corneal opacity

Unlike some related conditions, corneal clouding is usually mild or absent in Hunter syndrome, but eye changes can still affect vision and are monitored.

Limited evidenceCurated reference: ORPHA:580

Evidence ratingweak

Study designontology_import

Confidence (0-1)0.7

Replicationunreplicated

Supporting sourcesPMID:40102994

Notesplain_language confirmed from PMID:40102994 via curation 2026-06-18 [claude (tier3 curation)].

Last reviewed2026-06-18

How it is diagnosed

Mucopolysaccharidosis, type II

Diagnosed using: Urinary glycosaminoglycans (GAG) and IDS enzyme assay.

Limited evidenceSource: PMID:42033570

The source text this rests on

“…markedly reduced IDS activity and elevated urinary…”

An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.

Evidence ratingweak

Confidence (0-1)0.7

Replicationunreplicated

Notesconfirmed from PMID:42033570 via curation 2026-06-18

Last reviewed2026-06-18

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

idursulfase

Idursulfase is enzyme replacement therapy for MPS II: a manufactured copy of the missing iduronate-2-sulfatase enzyme, given by weekly intravenous infusion. It reduces stored glycosaminoglycans and can improve walking capacity, liver and spleen size, and other body-wide effects, but it does not cross well into the brain, so it has limited effect on the central-nervous-system disease of the severe form.

Used to help with: Mucopolysaccharidosis, type II.

Limited evidenceSource: PMID:40981299

The source text this rests on

“Enzyme replacement therapy (ERT), idursulfase, is the only FDA-approved treatment for MPS II.”

An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.

Evidence ratingweak

Confidence (0-1)0.7

Replicationunreplicated

Notesconfirmed from PMID:40981299 via curation 2026-06-14

Last reviewed2026-06-14

hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation is used in some patients with mucopolysaccharidoses, supplying donor cells that produce the missing enzyme. Its role in MPS II is less clearly established than in severe MPS I, particularly for protecting the brain, and decisions are individualized.

Used to help with: Mucopolysaccharidosis, type II.

Limited evidenceSource: PMID:40102994

The source text this rests on

“Allogeneic hematopoietic stem cell transplantation (HSCT) has proven to be a viable treatment option for patients with mucopolysaccharidoses (MPS).”

An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.

Evidence ratingweak

Confidence (0-1)0.7

Replicationunreplicated

Notesconfirmed from PMID:40102994 via curation 2026-06-14

Last reviewed2026-06-14

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.

Strong evidenceBacked by solid, repeated research.

Moderate evidenceReasonable evidence, still being confirmed.

Limited evidenceSome evidence, but not yet convincing.

Early evidenceAn early finding that needs more study.

Experts disagreeResearchers actively disagree about this.

No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 12 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:309900 · Orphanet/HPO annotations for Mucopolysaccharidosis, type II

ORPHA:580 · Orphanet/HPO annotations for Mucopolysaccharidosis type 2

PMID:18245410 · Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

PMID:27829684 · Comparative study of idursulfase beta and idursulfase in vitro and in vivo.

PMID:38053935 · Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey.

PMID:40102994 · Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life.

PMID:40981299 · Novel Phenotypic Insights into the IDS c.817C>T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts.

PMID:41017152 · Non-neurological, non-skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy (OTL-203) for Hurler syndrome.

PMID:41858182 · The Diagnostic Odyssey of a Biochemically Confirmed Case of ML II: The First Western Patient With LYSET Deficiency.

PMID:41964217 · Heterozygous CECR2 variants support a distinct neurodevelopmental syndrome with features overlapping cat eye syndrome.

PMID:42033570 · A novel IDS variant associated with an isolated ocular phenotype in Hunter syndrome.

PMID:42107344 · Natural history of hearing loss in adults with mucopolysaccharidoses across phenotype and genotype.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.

Get the Condition Packet Get the Medical Necessity Evidence Dossier